🔍 What This Document Is

This is a Form 6-K filing from Inventiva, a French-American biotech company. It's essentially their 2025 annual report wrapped in a press release, giving investors a full business and financial update. It explains how they spent their money, what progress they made on their main drug, and how they plan to fund their future work.

🏢 What The Company Does

In simple terms, Inventiva is a biotech startup working on new medicines for a serious liver disease called MASH (Metabolic dysfunction-associated steatohepatitis). Their lead drug, lanifibranor, is an oral pill in a Phase 3 clinical trial—the final big test before potential approval. They are a "clinical-stage" company, meaning they are focused on research and development but aren't selling any approved products of their own yet.

💰 Financial Highlights: The 2025 Scorecard

• Revenue: €4.5 million, down from €9.2 million in 2024. This is mostly from milestone payments from a partner, not from product sales.
• Cash is King: This is the most critical number for a pre-revenue biotech.
  • Cash & equivalents: €99.3 million
  • Short-term deposits: €131.6 million
  • Total liquid assets: €230.9 million as of Dec 31, 2025.
• The Burn Rate: They spent a net €104.9 million on operations in 2025 (up 22% from 2024). This is the cash "burned" to fund research and run the company.
• The Big Loss: Net loss ballooned to €354.1 million from €184.2 million in 2024. A huge part of this loss (€179.8 million) was due to complex accounting rules related to financing deals—it's mostly "paper losses," not cash leaving the company.

👉 The bottom line: They have a strong cash cushion right now, but they are spending heavily to fund their crucial Phase 3 trial.

🚀 Key Moves in 2025

• Big Fundraise: They raised about $172.5 million (€149 million) from a public stock offering in the U.S. in November 2025. This was a major injection of cash.
• Sold a Pipeline Asset: They sold all rights to a preclinical drug called odiparcil to a company called Biossil. They got $600,000 upfront and could get up to $90 million in future milestones plus royalties if Biossil successfully develops and sells it.
• Strategic Prioritization: They refocused their efforts and spending almost entirely on lanifibranor for MASH, which explains some of the cost changes.

👉 Why it matters: The fundraising ensures they have the money to finish the critical trial. Selling odiparcil lets them focus resources while keeping a chance at future payoffs.

📦 Financial Position & Cash Runway

This is the most important forward-looking part of the report.

• With their current cash and spending rate, management estimates they have enough money to operate until the middle of the first quarter of 2027.
• There's a potential extra funding boost (up to €116 million) from investor warrants that, if exercised, could extend the runway to the middle of the third quarter of 2027.

👉 Why it matters: This tells investors the "zero date"—when the company would run out of money without new funding or a successful drug outcome. The clock is ticking toward their big trial result.

🧪 The Clinical Trial Countdown

The entire company's near-term future hinges on one clinical trial:

• Drug: Lanifibranor
• Trial Name: NATiV3 (Phase 3)
• Disease: MASH with advanced fibrosis (scarring)
• Status: Patient enrollment was completed in April 2025.
• Next Event: Topline results are expected in the fourth quarter of 2026. This is the moment of truth that will determine if the drug works.

👉 Why it matters: Positive results could lead to an application for drug approval and a potential launch. Failure would be catastrophic for the company's current strategy.

⚖️ The Big Picture: Strengths & Risks

• Strengths (👍):
  • Strong Cash Position: Well-funded through the critical trial readout.
  • Focused Strategy: All resources are pointed at the high-stakes lanifibranor program.
  • Experienced Team: Recent appointments of a new CEO, CMO, and other executives suggest a seasoned team is in place for potential commercialization.
• Risks (⚠️):
  • Binary Risk: Everything depends on the NATiV3 trial results in late 2026. It's a high-risk, high-reward situation.
  • Cash Burn: They are spending over €100 million per year with no product revenue. The runway is finite.
  • Going Concern Warning: The filing notes their auditors will include a warning about "material uncertainty related to going concern," which is standard language for companies that aren't yet profitable but highlights the risk.

🧠 The Analogy

Inventiva is like a climber on a critical ascent. They've spent years training and climbing (R&D), and they've just secured enough supplies (cash) to reach the final, most challenging ledge (the Phase 3 trial result). The entire expedition's success hinges on whether that ledge is solid (positive trial data). The team they've assembled (new executives) is preparing ropes and gear (regulatory/commercial plans) in advance, but until they test the ledge, it's a moment of intense focus and risk.

📇 Key Contacts & People

• Investor Relations:
  • David Nikodem: [email protected]
  • Patricia L. Bank: [email protected]
• Media Relations:
  • Pascaline Clerc: [email protected]
  • Alexis Feinberg: [email protected]
• Key Executive: Andrew Obenshain, CEO

🧩 Final Takeaway

Inventiva has successfully built a financial bridge to the most important moment in its history: the Phase 3 trial results for its MASH drug, expected in late 2026. The company is now a "one-binary-event" story, where the next 18 months will be defined by preparation for, and then the outcome of, that single clinical readout.